Targets › IGFBP2
3 programs from 2 companies in 3 trials: 3 Phase 2; Oncology; next expected readout Dec 2026.
Multifunctional protein that plays a critical role in regulating the availability of IGFs such as IGF1 and IGF2 to their receptors and thereby regulates IGF-mediated cellular processes including proliferation, differentiation, and apoptosis in a cell-type specific manner. Functions coordinately with receptor protein tyrosine phosphatase beta/PTPRB and the IGF1 receptor to regulate IGF1-mediated signaling by…. (UniProt, P18065)
Open in Phaseline: the race on IGFBP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Washington | pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine (WOKVAC) Plasmid DNA vaccine encoding tumor-associated antigens (IGFBP2, HER2, IGF1R) to stimulate | IGFBP2, HER2, IGF1R | Phase 2 | Anatomic Stage I Breast Cancer AJCC v8 | Dec 2026 |
| University of Washington | pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine Plasmid DNA vaccine targeting IGFBP-2 protein to stimulate immune response against ovarian | IGFBP2 | Phase 2 | Fallopian Tube Carcinoma | Sep 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | WOKVAC pUMVC3-based vaccine targeting IGFBP2, HER2, and IGF1R | IGFBP2, ERBB2, IGF1R | Phase 2 | Breast Cancer Female | Dec 2027 |
Fallopian Tube Carcinoma (1) Anatomic Stage I Breast Cancer AJCC v8 (1) Breast Cancer Female (1)
mixed (2), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.